Last Updated : October 10, 2024
Details
FilesGeneric Name:
Nab-paclitaxel
Project Status:
Complete
Therapeutic Area:
Gastrointestinal cancer
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0354-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Fee Schedule:
Pending
Indications:
In combination with gemcitabine, for previously treated advanced (locally advanced unresectable or metastatic) pancreatic cancer
Recommendation Type:
Do not reimburse
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Call for patient/clinician input open | 02-Jan-24 |
---|---|
Call for patient/clinician input closed | 26-Feb-24 |
Call for industry input open | 02-Jan-24 |
Call for industry input closed | 26-Feb-24 |
Submission received | 21-Dec-23 |
Draft recommendation posted for stakeholder feedback | 01-Aug-24 |
End of feedback period | 16-Aug-24 |
Files
Last Updated : October 10, 2024